☸️ SAIMSARA — Public Sessions

Carotid stenosis outcomes are not determined by narrowing alone: this review shows how symptom status, procedure choice, restenosis, and plaque vulnerability markers can decisively shift stroke risk and long-term prognosis. Read the full paper to see which patients appear to benefit from intervention, where CEA and CAS truly diverge, and why modern risk stratification may need to move beyond luminal stenosis.

This paper shows that in carotid stenosis, the real difference is not only who gets operated on, but who receives and continues the right medical therapy. It is worth reading because it identifies the medication strategies that most consistently align with better outcomes and exposes adherence as a major, underappreciated driver of prognosis.

This paper shows that carotid stenosis is not just a problem of how narrow the artery looks: inflammation repeatedly emerges as the hidden biology that helps explain which plaques become dangerous, embolize, and lead to recurrent stroke. The full review is worth reading because it maps where PET imaging, blood biomarkers, and anti-inflammatory strategies may move carotid care beyond stenosis grading alone toward a more precise, risk-based treatment model.

This paper shows that CT angiography in carotid stenosis is not just about measuring narrowing: it can reveal plaque vulnerability, near-occlusion, carotid webs, and hidden stroke risk that standard stenosis thresholds may miss. It is worth reading because it maps where CT truly adds clinical value, where it can mislead, and how more structured CTA reporting could change decision-making.

This paper shows that carotid shunts are neither universally protective nor universally harmful: they can reduce stroke risk in selected high-risk carotid surgery patients, but they also introduce their own complications. It is worth reading because it maps when shunting may truly help, when it may be unnecessary, and how monitoring can guide a safer, more tailored surgical strategy.

This paper shows that carotid-related stroke is not primarily a story of narrowing alone, but of vulnerable plaque biology, hidden high-risk lesions, and smarter individualized selection between medical therapy, surgery, and stenting. The full review is worth reading because it maps where modern carotid care is genuinely shifting, from stenosis percentage toward plaque-driven, multimodal stroke risk stratification.

Blue toe syndrome is not just a toe finding — it is a warning signal for distal microembolization, systemic vascular risk, and hidden hematologic, autoimmune, malignant, procedural, or mechanical causes. This SAIMSARA evidence map turns scattered case-level and cohort evidence into a structured diagnostic and treatment roadmap for clinicians and AI agents needing citation-linked BTS reasoning.

This review turns 1,815 original studies and 919,224 participants into a structured evidence map showing when barefoot walking/running may improve mechanics, balance, foot strength, or knee loading — and when it becomes clinically risky. It is especially useful for clinicians, runners, coaches, and researchers who need a clear, citation-linked map of barefoot biomechanics, diabetic-foot risk, falls, infection exposure, and safe transition strategies.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.

This review shows that atherosclerosis is not merely a late-life clinical disease, but a widespread silent substrate detectable across middle age, inflammatory disease, metabolic risk, genetic susceptibility, and even apparently low-risk populations. The full paper is worth reading because it maps where conventional risk scores may underestimate real vascular burden—and where selective imaging could redefine prevention.

This paper shows that asymptomatic carotid stenosis is no longer a simple “operate-or-observe” problem: under modern medical therapy stroke risk is often lower than once feared, yet a biologically high-risk subgroup still emerges through plaque vulnerability, hemodynamic failure, microemboli, and covert brain injury. The full review is worth reading because it maps where intervention may still matter, where overtreatment is likely, and how the field is shifting from stenosis percentage alone toward truly individualized risk stratification.

This review shows where clopidogrel truly outperforms aspirin, where the advantage disappears, and why the answer changes across PCI, stroke, PAD, gastrointestinal risk, and surgery. It turns a common everyday antiplatelet choice into a clinically practical evidence map of who may benefit more from clopidogrel, when aspirin may still be safer, and where the real uncertainties remain.